Alvotech (NASDAQ:ALVO) Trading 6.8% Higher – Here’s What Happened

Alvotech (NASDAQ:ALVO) shot up 6.8% on Thursday . The company traded as high as $4.37 and last traded at $4.26. 796,346 shares traded hands during trading, an increase of 25% from the average daily volume of 638,732 shares. The stock had previously closed at $3.99.

Trending Headlines about Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Alvotech resubmitted U.S. biologics license applications for AVT05, a proposed Simponi/Simponi Aria biosimilar, and AVT06, a proposed Eylea biosimilar. Its partner, Dr. Reddy’s Laboratories, also resubmitted the AVT03 application for a Prolia/Xgeva biosimilar. FDA decisions are expected in the fourth quarter of 2026, creating significant regulatory catalysts. Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
• Positive Sentiment: The FDA closed its inspection of Alvotech’s Reykjavik manufacturing facility with a VAI classification, supporting management’s view that manufacturing and quality-system improvements are progressing. The company said production returned to planned levels late in the second quarter and that it is rebuilding supply to meet confirmed demand. Alvotech Business Update
• Positive Sentiment: Management reaffirmed a 2026 revenue outlook of $650 million to $700 million and adjusted EBITDA guidance of $180 million to $220 million. The revenue range’s midpoint is above the roughly $657.4 million analyst consensus, suggesting confidence in a stronger second half. Alvotech Reports Q2 Loss and Revenue Guidance
• Positive Sentiment: Alvotech raised approximately $165 million through an equity offering and private placement and added a $75 million term loan, improving funding for pipeline development and working capital.
• Neutral Sentiment: Second-quarter revenue of $105.77 million exceeded estimates of $103 million, but adjusted first-half revenue fell 30.8% year over year to $211.9 million as product and service revenue declined 48.3%. Alvotech Quarterly Results
• Negative Sentiment: Alvotech reported a quarterly loss of $0.11 per share, wider than the $0.05 expected loss and down from earnings of $0.14 per share a year earlier. Adjusted EBITDA also declined 12.7% to $46.9 million, while cash fell to $142.8 million from $172.4 million at the end of 2025. The new financing strengthens liquidity but increases dilution and debt obligations. Alvotech Q2 Earnings Report

Wall Street Analysts Forecast Growth

A number of research firms have commented on ALVO. Wall Street Zen cut shares of Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings cut shares of Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Finally, Evercore assumed coverage on shares of Alvotech in a report on Friday, August 14th. They issued an “outperform” rating on the stock. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.60.

Alvotech Stock Up 4.8%

The firm has a market cap of $1.26 billion, a PE ratio of -16.72 and a beta of 0.18. The business has a 50-day moving average price of $3.66 and a two-hundred day moving average price of $3.75.

Alvotech (NASDAQ:ALVO) last issued its earnings results on Thursday, August 20th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.06). Alvotech had a negative net margin of 14.36% and a negative return on equity of 11.92%. The firm had revenue of $105.77 million during the quarter, compared to analyst estimates of $103.00 million. On average, equities research analysts predict that Alvotech will post 0.05 earnings per share for the current fiscal year.

Institutional Trading of Alvotech

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Alvotech by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock valued at $35,481,000 after buying an additional 114,255 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Alvotech by 1,707.7% during the fourth quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock worth $1,832,000 after buying an additional 337,417 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Alvotech by 88.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after acquiring an additional 122,089 shares during the period. Geode Capital Management LLC increased its position in Alvotech by 10.7% in the 4th quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock valued at $1,308,000 after acquiring an additional 24,667 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC purchased a new stake in Alvotech during the 2nd quarter valued at approximately $1,782,000.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).